Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosisPRNewsWire • Thursday
Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?Zacks Investment Research • 11/11/26
3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years24/7 Wall Street • 11/07/26
These 12 stocks are good bets to beat the 10-year Treasury over the next decadeMarket Watch • 11/04/26
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of strokePRNewsWire • 11/02/26
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy SystemPRNewsWire • 11/01/26
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseasePRNewsWire • 10/29/26
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks24/7 Wall Street • 10/27/26
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?Zacks Investment Research • 10/27/26
Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds AheadSeeking Alpha • 10/27/26
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPRNewsWire • 10/26/26